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Abstract
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-
related death in female. To better understand the growth and progression as well as 
therapeutic management, breast cancers are grouped based on histopathological and 
molecular classification. A number of factors have been implicated in the development 
of breast cancer. Various cell surface as well as hormone receptor signaling play crucial 
role in breast cancer initiation and progression. This chapter briefly discusses few of the 
important receptor signaling pathways and the various strategies in practice as well as at 
different stages of development to target these pathways.
Keywords: breast cancer, estrogen receptor, HER1, HER2, tyrosine kinase inhibitors, 
WNT signaling, therapeutic monoclonal antibodies
1. Introduction
Cancer is considered to be the leading cause of death in developed countries and the 
second in developing countries. The burden of cancer is growing in economically devel-
oping countries due to population aging and adaption of cancer-associated lifestyle 
including smoking and Western diet. In 2008, it has been estimated that around 12.7 
million cancer cases and 7.6 million cancer deaths have happened. Of these about 56% 
of the cases and 64% of the deaths have been recorded in the economically developing 
countries [1].
Breast cancer in female is the most common diagnosed cancers and the leading cause of 
cancer-related death in developed and developing countries. It accounted for 1.38 million 
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new cancer cases (23%) and 458,400 (14%) of the total cancer deaths in 2008 worldwide. Of 
these, about 50% of the cases of breast cancer and 60% of breast cancer deaths takes place in 
 developing countries including Western and Northern Europe, North America, Australia and 
New Zealand [2]. In the United States, in 2008, the American Cancer Society (ACS) estimates 
that almost 182,500 women were diagnosed with breast cancer and during the year about 
40,500 women lost their life due to breast cancer.
The breast is made up of different types of tissues including fatty, lymphatic and connective 
tissue. A female breast is organized into 15–20 sections called lobes. Each of these lobes con-
tains many smaller glandular structures called lobules which responsible for milk produc-
tion. The lobes and lobules are connected through a network of tubes called ducts through 
which milk flows and reaches the nipple [3].
Majority of breast cancers arise from the cells in the duct or from milk-producing cells in the 
lobules. Increase in the incidence of breast cancer observed in epidemiological studies is as 
a result of breast cancer risk factors. About 20–30% of diagnosed cancer cases may be asso-
ciated with these factors and their activity that lead to deregulation of the normal cellular 
processes into neoplastic transformation of breast cells [4]. However, about 75–80% of women 
with breast cancer have no identifiable risk factor [4]. Therefore, different system or model is 
required to be utilized to examine this cancer.
2. Risk factors of breast cancer
Being a women and getting older are the main influence to have breast cancer. It has been 
reported that women with age 30has a lower chance (about 1 in 1500) of developing breast 
cancer compared to women with age 40 (about 1 in 173) [5]. Thus, being 40 years of age or 
above poses significant risk for developing breast malignancy. There are several other factors 
that play crucial role in developing breast cancer, such as history of cancer in first-degree rela-
tives, history of mammary gland diseases, early menarche, late menopause, Caucasian race, 
and late childbearing after 35 years of age. Causes of breast cancer development have also 
been linked to lifestyle-related factors including alcohol consumption, not being physically 
active, being overweight or obese and using hormone replacement therapy. Risk of having 
breast cancer may result from combination for these factors as reviewed by Singletary [6] as 
can be seen in Table 1.
Breast cancer classification systems have been utilized in order to organize the heterogeneity 
of this disease. Over many decades, these systems have been developed in order to assist in 
prognosis and treatment. The breast cancer classification models evolved due to advances in 
cancer research and understanding of the molecular heterogeneity of breast cancers. These 
classifications are based on histological and molecular variations in breast cancer subtypes 
[7]. Such classifications assist in understanding the growth and progression of breast cancer 
as well as in their therapeutic management.
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Risk factor Category at risk Comparison category Relative 
risk
Alcohol intake 2 drinks per day Non-drinker 1.2
Body mass index 80th percentile, age 55 or greater 20th percentile 1.2
Hormone replacement therapy 
with estrogen and progesterone23
Current user for at least 5 years Never used 1.3
Radiation exposure Repeated fluoroscopy No exposure 1.6
Radiation therapy for Hodgkin’s 
disease
No exposure 5.2
Early menarche Younger than 12 years Older than 15 years 1.3
Late menopause Older than 55 years Younger than 45 1.2–1.5
Age at first childbirth Nulliparous or first child after 30 First child before 20 1.7–1.9
Current age 65 or older Less than 65 5.8
Past history of breast cancer Invasive breast carcinoma No history of invasive 
breast carcinoma
6.8
Other histologic findings Lobular carcinoma in situ No abnormality detected 16.4
Ductal carcinoma in situ No abnormality detected 17.3
Breast biopsy Hyperplasia without atypia* No hyperplasia 1.9
Hyperplasia with atypia No hyperplasia 5.3
Hyperplasia with atypia and 
positive family history
No hyperplasia, negative 
family history
11
Cytology (fine-needle aspiration, 
nipple aspiration fluid)
Proliferation without atypia* No abnormality detected 2.5
Proliferation with atypia No abnormality detected 4.9–5
Proliferation with atypia and 
positive family history
No abnormality detected 18.1
Family history 1st-degree relative 50 years or older 
with postmenopausal breast cancer
No 1st- or 2nd-degree 
relative with breast cancer
1.8
1st-degree relative with 
premenopausal breast cancer
No 1st- or 2nd-degree 
relative with breast cancer
3.3
2nd-degree relative with breast 
cancer
No 1st- or 2nd-degree 
relative with breast cancer
1.5
Two 1st-degree relatives with breast 
cancer
No 1st- or 2nd-degree 
relative with breast cancer
3.6
Germline mutation Heterozygous for BRCA1, age < 40 Not heterozygous for 
BRCA1, age < 40
200
Heterozygous for BRCA1, age 60–69 Not heterozygous for 
BRAC1, age 60–69
15
*There is controversy over whether pathologic hyperplasia detected in breast biopsy samples is directly equivalent to 
cytologic hyperplasia detected in samples obtained through FNA or nipple aspiration.
Table 1. Risk factors for breast cancer.
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3. Classification of breast cancer
3.1. Histopathological classification
Breast cancer can be broadly classified based on the location and aggressiveness of the 
disease. Two main classes of breast cancer are in situ carcinoma and invasive (infiltrat-
ing) carcinoma. Breast carcinoma in situ can be divided into two types. Ductal carcinoma 
in situ (DCIS) originates from the cells lining the ducts that transport milk to the nipple 
while lobular carcinoma in situ (LCIS) occurs in the cells of lobules, the milk-producing 
glands at the end of breast ducts [3, 7]. Both DCIS and LCIS are premalignant lesions that 
do not invade deeper or spread through the body. Women with these lesions have higher 
likelihood of getting cured but also have increased risk of developing invasive breast can-
cer in the future. DCIS is significantly more common accounting for 80–90%, while LCIS 
accounts for 10–20% of breast cancer cases [3]. DCIS has been traditionally sub-classified to 
five well-recognized subtypes as Solid, Papillary, Micropapillary, Cribriform and Comedo 
based on the architectural features of the tumor [8]. Invasive carcinomas, similar to in situ 
carcinomas are differentiated into histological subtypes. These subtypes include infiltrating 
Figure 1. Histological classification of breast cancer subtypes. Modified from Malhotra et al., 2010 [7].
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ductal (IDC), invasive lobular (ILC), mucinous (colloid), medullary, tubular and papillary 
carcinomas (Figure 1) [7]. IDC is considered as the most common histological subtype of 
breast cancer, and it accounts for 70–80% of all invasive lesions [9], while ILC is the second 
most prevalent and accounts for roughly 10% of all breast cancers. These subtypes dif-
fer from each other based on clinicopathologic aspects, natural history, epidemiology and 
molecular alterations [10].
3.2. Molecular classification
Breast cancer is a heterogeneous disease with diverse histological and molecular variations 
determining the biological behavior and therapeutic response. The occurrence as well as 
death due to breast cancer is on the rise globally despite advances in the development of 
diagnostic techniques and medications. There are many factors including age, family his-
tory, receptor status and others that have been investigated to assess patients’ risk and treat-
ment selection. It has been proven that receptor status is the most valuable in determining 
prognosis and responsiveness to therapy [11, 12]. Based on the receptor status, breast can-
cers are divided into three main groups. The first group includes estrogen receptor (ER) or 
progesterone receptor (PR) positive, while the second group comprises tumors that tested 
positive for human epidermal growth factor receptor 2 (HER2) with or without ER and PR 
positivity. Finally, triple-negative breast cancer (TNBC) is defined by the absence of ER/
PR expression and HER2 amplification [11]. Targeted therapy is available for breast cancer 
patients that express ER, PR or HER2 receptors; however, no standard treatment options are 
in practice for TNBC patients. Traditional chemotherapeutic regimens are utilized for this 
type of patients [13].
A number of techniques including immunohistochemistry (IHC), DNA microarray tech-
nology, fluorescent in situ hybridization (FISH) are utilized to reveal molecular differences 
within the same or different histopathological specimens [14–16]. Using IHC and DNA micro-
arrays lead to the identification of five discrete subtypes of breast cancer. These subtypes 
include luminal A (ER+ and/or PR+ and HER2−), luminal B (ER+ and/or PR +and HER2+), HER2 
overexpressing (ER− and PR−, HER2+), basal-like (ER−/PR−/HER2−, cytokeratin 5+/6+ and/or epi-
dermal growth factor receptor (EGFR)+) and normal breast-like. These different breast cancer 
subtypes are diverse in prognosis and therapeutic management [11]. Microarray classifica-
tion of breast cancer is represented in Table 2. This classification is based on two types of 
epithelial cells including luminal and basal cells (and/or myoepithelial) in human mammary 
gland. These cells can be identified using IHC technique as luminal cells express ER and PR 
receptors and keratins 8+/18+, whereas basal cells are keratins 5+/6+ and 17+ [17, 18].On the other 
hand, TNBC can be identified by ER−, PR− and HER2− using IHC range between 0 and 1 or by 
FISH negative if 2+ on IHC [15].
Various receptors including estrogen receptor (ER) and other growth factor receptor signaling 
pathways play an important role in breast cancer initiation and progression. Targeting these 
receptors by specific inhibitors may lead to the inhibition of tumor growth [20].
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Subtypes ER, PgR, Her 2 
Status
Other IHC features Cell of origin Other characteristics
Luminal A ER + or PgR + or 
both, Her 2-
Keratin 8/18 + ve Luminal epithelial cell Younger age
Best prognosis
Low rates of recurrence
Higher survival rate
Luminal B ER + or PgR + or 
both, Her 2+
Keratin 8/18 + ve Luminal epithelial cell Higher tumor grade
Poorer prognosis
Basal-like ER-, PgR-, 
Her2−/+
Keratin 5/6/17 + ve Basal/myoepithelial cell/
Bipotent progenitor
15%
EGFR + ve Younger age
Associated with hereditary 
BRCA 1
Poorer prognosis compared 
to other types
Spread to axillary nodes, less 
common to bones
Her 2+ ER-, PgR-, Her2+ — Late luminal progenitor 20–25%
Poorer grade
Lymph nodes positive
Early distant metastases
Poor prognosis
Frequent relapse
Normal 
breast-like
Tumors that 
do not fill into 
any of these 
categories
— Luminal epithelial cell 6–10% of all breast cancers
Small tumors
Good prognosis
More common in 
postmenopausal
Associated with 
fibroadenomas
Claudin low ER-, PR-, Her2- Mesenchymal 
markers
Stem cell 5–10% of all tumors
Typically triple negative
Low expression of cell-cell 
junction proteins (like 
E-Cadherin)
Lymphocytic infiltrates
IHC, immunohistochemistry; ER, estrogen receptor; PgR, progesterone receptor, +, positive, − negative.
Table 2. Microarray classification of breast cancer [19].
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4. Breast cancer receptors (ER, PR and HER2) and their involvement 
in cancer progression
4.1. Estrogen receptor (ER)
Despite the fact that a large number of potentially valuable factors have been identified, only 
three receptors, the estrogen receptor-alpha (ERα), the progesterone receptor (PgR), and the 
HER2 are utilized in clinical practice, and their assessment is obligatory [21]. Approximately 
70% of all breast cancers, which belong to the molecular subtypes luminal A or luminal 
B, express ERα. There is strong evidence demonstrating that estrogen plays an important 
role in the progression and development of breast cancers, although the causes behind 
these malignancies still remains uncertain [22]. ER alpha positive breast cancers depend on 
estrogen signaling for proliferation. Binding of estrogen to ERs leads to dimerization of the 
receptor which then translocates to the nucleus and binds estrogen response elements in the 
DNA sequence. This leads to cell proliferation as a result of stimulation of target genes [23]. 
ERα mediates a number of molecular signaling such as mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase (PI3K) pathways which are involved in cell growth 
and proliferation [24] as can be seen in Figure 2.
Figure 2. The PI3K/AKT/mTOR and the RAS/RAF/MEK/MAPK pathways. Modified from Toss and Cristofanilli [25].
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ERα-positive breast cancer depends on these signaling for proliferation. Therefore, the most 
effective approach to terminate or slow the growth of this type of cancer is by blocking estro-
gen action in the tumor using hormone therapies. For the past few decades, one of the most 
widely used drug for the treatment of breast cancer is tamoxifen, which is a selective ER 
modulator and acts as anantagonizer for ERα function. It has been utilized as a long-term 
adjuvant therapy and as preventative agent in a lot of women at increased risk for the disease. 
Also, fulvestrant, which acts as an anti-estrogen, downregulates ERα and has been approved 
for clinical use [22].
Another class of breast cancer treatment drugs that have evolved are called aromatase inhibi-
tors (AIs). These inhibitors include anastrozole, letrozole and exemestane as detailed in 
Table 3. AIs are able to inhibit the aromatase enzyme (a cytochrome P450 heme-containing 
protein), which is required for estrogen synthesis [26] During menopause, the level of estro-
gen decreases due to cessation of estrogen production by the ovaries. Hence, locally syn-
thesized estrogen via breast adipose tissue plays crucial role in the survival and growth of 
ERα-positive breast tumors [27].Unfortunately, majority of patients treated with endocrine 
therapy develop resistance. This leads to the progression of disease and fatality. Several signal 
transduction pathways such as MAPK and PI3K are involved in tamoxifen resistance. These 
pathways are activated by growth factors including human epidermal growth factor receptor 
2 (HER2). It has been noticed that MCF-7/HER2–18 tamoxifen-resistant model system that 
overexpress HER2 shows increased growth when cells are treated with tamoxifen. Several 
studies indicate that there exists a molecular cross-talk between the ER and HER2 pathways 
[28, 29]. Also, the mechanisms associated with AIs resistance share similarities with tamoxifen 
resistance, particularly in the upregulation of growth factor pathway such as HER2 and its 
dimerization partner epidermal growth factor receptor (EGFR/HER1) [30].
Retinoblastoma (RB) is the tumor suppressor protein that plays an important role in regulat-
ing the progression of cell cycle. This occurs by the RB inhibitory action on E2Fs which are a 
family of transcription factors that are crucial for the expression of S-phase genes. It has been 
noticed that deregulation in the RB pathway occurs in various cancers including breast cancer 
2. About 50% of breast cancers overexpress cyclin D1 that lead to an aberrant phosphorylation 
of RB facilitating cell cycle progression [31]. Adjuvant tamoxifen-treated ER positive breast 
cancer patients having functional RB pathway have fewer breast cancer recurrences, while 
those with RB non-functional tumors have no benefit of tamoxifen. Therefore, knowing the 
RB status in breast cancer can be utilized as predictive factor to identify patients who will ben-
efit from tamoxifen therapy [32]. Further, it has been observed that histone demethylase reti-
noblastoma-binding protein 2 (RBP2) has a potential to develop endocrine therapy resistance 
in breast cancer. Choi et al. demonstrated that tamoxifen resistance in vitro and in vivo occurs 
as a result of RBP2 overexpression, while knocking down RBP2 imparted tamoxifen sensitiv-
ity. The cooperation between RBP2 and ER coactivators and corepressors regulates a number 
of tamoxifen resistance-associated genes. Moreover, RBP2 increased IGF1R-HER2 cross-talk 
that lead to PI3K-AKT activation through demethylase activity-independent HER2 protein 
stabilization. Therefore, RBP2-mediated tamoxifen resistance might be overcome using com-
binational treatment with PI3K inhibitor and tamoxifen. ER-IGF1R-HER2 signaling cascade 
can be activated in various ways by RBP2 to induce tamoxifen resistance, thus making RBP2 
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Drug Target Indications/trials
Tamoxifen ER Treatment of metastatic estrogen receptor positive breast cancer.
Adjuvant treatment of node-positive breast cancer in postmenopausal 
women following total mastectomy or segmental mastectomy.
Adjuvant treatment of axillary node-negative breast cancer in women 
following total mastectomy or segmental mastectomy.
Fulvestrant ER Hormone receptor (HR)-positive, human epidermal growth factor 
receptor 2 (HER2)-negative advanced breast cancer in postmenopausal 
women who have not been previously treated with endocrine therapy.
HR-positive advanced breast cancer in postmenopausal women whose 
disease has progressed after endocrine therapy
HR-positive, HER2-negative advanced breast cancer or breast cancer that 
has spread to other parts of the body (metastatic), in combination with 
palbociclib or abemaciclib in women whose disease has progressed after 
endocrine therapy.
Anastrozole Aromatase enzyme Adjuvant treatment (treatment following surgery with or without 
radiation) of postmenopausal women with hormone receptor positive 
early breast cancer approved for the initial treatment of postmenopausal 
women with hormone receptor positive or hormone receptor-unknown 
locally advanced or metastatic breast cancer and for the treatment of 
postmenopausal women with advanced breast cancer that has progressed 
following treatment with tamoxifen.
Letrozole Aromatase enzyme Adjuvant treatment of postmenopausal women with estrogen receptor 
positive early breast cancer.
Exemestane Aromatase enzyme Adjuvant treatment of postmenopausal women with estrogen receptor 
positive early breast cancer who have received 2–3 years of tamoxifen and 
are switched to exemestane for completion of a total of five consecutive 
years of adjuvant hormonal therapy.
Trastuzumab HER2 Treatment of patients with HER2-overexpressing breast cancer.
Pertuzumab HER2 Used in combination with trastuzumab and chemotherapy as adjuvant 
treatment of patients with HER2-positive early breast cancer at high risk 
of recurrence.
T-DM1 HER2 Used for the treatment of patients with metastatic HER2-positive breast 
cancer.
Cetuximab HER1 Pre-clinical and clinical studies especially in combination therapy to treat 
triple-negative breast cancer.
Panitumumab HER1 Phase II study of Panitumumab, Nab-paclitaxel, and Carboplatin for 
patients with primary inflammatory breast cancer (IBC) without HER2 
overexpression.
Erlotinib HER1 Phase I study of Erlotinib and Metformin in triple-negative breast cancer.
Pre-clinical studies in triple-negative breast cancer.
Lapatinib HER2/HER1 Treatment of postmenopausal women with hormone receptor positive 
metastatic breast cancer that overexpresses the HER2 receptor and for 
whom hormonal therapy is indicated.
Neratinib HER2/HER1 Adjuvant treatment of adult patients with early stage HER2-
overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-
based therapy.
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as a potential therapeutic target for ER-driven cancer [33]. Despite these findings the mecha-
nisms of endocrine therapy resistance are poorly understood making it a major challenge in 
the clinical management of this disease.
4.2. Progesterone receptor (PR)
Human breast cancers rely on estrogen and/or progesterone hormones for growth, and this 
effect is mediated through ERs and PRs. ER or PR positive tumors represent up to two thirds 
of invasive breast cancers in women whose age are less than 50 years, while about 80% of 
tumors in women with age above 50 years are ER positive [34]. ERα regulates the expression 
of PR. Therefore, the detection of PR normally indicates that the estrogen-ERα pathway is 
intact and functional. Once PR is expressed, the hormone progesterone activates PR leading 
to the upregulation of several crucial cellular function such as proliferation contributing to 
breast cancer growth [21]. One of the most important parameter in breast cancer management 
is determining the response of tumor to hormone therapy as not all patients benefit from these 
therapies. Patients with breast cancer overexpressing ERs and PRs are more likely to respond 
to hormone therapy, while tumors negative for these receptors are unlikely to get benefit from 
them and respond better to chemotherapy [35]. Hormone therapy provides better quality of 
living and improves survival. Higher expression level of PR is associated with better hormone 
therapy response, increased survival rate and longer time for treatment failure. It has been 
noticed that PR+ is correlated with higher hormone therapy response rate independent of ER 
Drug Target Indications/trials
RO4929097 γ-secretase inhibitor 
(NOTCH Pathway)
Pre-clinical and early clinical trial.
MRK-003 γ-secretase inhibitor 
(NOTCH Pathway)
Pre-clinical studies in animal models
MK-0752 γ-secretase inhibitor 
(NOTCH Pathway)
A pilot study in combination with tamoxifen or letrozole in patients with 
early stage breast cancer prior to surgery.
PF-03084014 γ-secretase inhibitor 
(NOTCH Pathway)
Pre-clinical studies and phase 2 trial in patients with advanced triple-
negative breast cancer with or without genomic alterations in notch 
receptors
Salinomycin LRP6 (Wnt/β-
catenin pathway)
Pre-clinical studies in animal models.
OMP-18R5 FZD7 (Wnt/β-
catenin pathway)
A phase 1b dose escalation in combination with paclitaxel in patients with 
locally recurrent or metastatic breast cancer.
OMP-54F28 FZD8 (Wnt/β-
catenin pathway)
Phase I study in patients with advanced solid tumors.
OTSA101 FZD10 (Wnt/β-
catenin pathway)
Yttrium 90-radiolabeled OTSA101 in phase I trial in patients with 
relapsed or refractory non-resectable synovial sarcomas
Table 3. Approved and investigational drugs targeting estrogen receptor and other signaling pathway components.
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despite the fact that the expression levels of ER and PR are correlated. Tumors with ER+/PR+ 
have higher response rate compared to ER+/PR−tumors. Thus, the status of PR provides essen-
tial information about how tumors will respond to hormone therapies [35].
4.3. Human epidermal growth factor receptor 2 (HER2)
Transmembrane receptor tyrosine kinases family (RTKs) consists of HER1 (epidermal growth 
factor receptor [EGFR]), HER2, HER3 and HER4. These receptors are involved in regulating 
a range of cellular processes that controls cell growth, differentiation, survival and migra-
tion. HER2 gene overexpression has been reported in 20–30% of patients with breast cancer 
[16, 36]. HER receptors are located at the plasma membrane and get activated by ligand 
binding to the extracellular domain. This binding induces the formation of homodimers or 
heterodimers [36]. While HER2 does not have a known ligand, HER3 is kinase-inactive and 
thus both these receptors signal by heterodimerization. Dimerization of these receptors leads 
to the phosphorylation of tyrosine residues within the receptor intracellular tyrosine kinase 
domain (cytoplasmic domain). These residues work as docking sites for adaptor proteins 
containing Src homology 2 and phosphotyrosine binding domains (PTB). These proteins acti-
vate a large number of signal transduction molecules such as stress-activated protein kinase 
and signal transducer and activator of transcription (STATs) and protein kinase B (PKB or 
AKT) and subsequent stimulation of downstream signaling pathways including STAT, PI3K 
and MAPK pathways. These signaling pathways are able to activate a wide range of cellular 
responses such as survival, proliferation, cell motility and differentiation [16]. Overexpression 
of HER2 and HER1 is responsible for poor clinical prognosis including unfavorable response 
to endocrine therapy in breast cancer patients.
4.4. HER1 and HER2 as therapeutic targets
There are two types of therapeutic strategies that have been utilized against breast cancers 
overexpressing HER1 and HER2 receptors. The first includes monoclonal antibodies (MAbs) 
that bind to the extracellular domain of the receptor interfering with the binding of endog-
enous ligands that activates these receptors. In the second strategy, small molecule inhibitors 
(tyrosine kinase inhibitors [TKIs]) bind to the tyrosine kinase domain and inhibit its kinase 
activity and subsequent downstream signaling (Figure 3 and Table 3) [16].
Anti-HER2 antibodies have been successfully utilized in the treatment of various cancers over-
expressing HER2 including breast cancer. These antibodies target the extracellular domain of 
HER2 and prevent receptor activation. Several monoclonal antibodies have been used includ-
ing trastuzumab and Pertuzumab. They bind to extracellular domain of HER2 in order to 
suppress its activity by preventing receptor dimerization and subsequent phosphorylation 
of the tyrosine kinase domain. As a result, the initiation of downstream signaling pathways 
gets precluded [37].In addition, a number of TKIs such as gefitinib, lapatinib and neratinib 
that are approved for treatment of breast cancers binds to HER1 and HER2 tyrosine kinase 
domains and inhibits their downstream signaling pathways [38]. A major clinical challenge in 
the treatment of HER2-positive breast cancer is due to resistance to the HER2-targeted anti-
body trastuzumab. Aghazadeh and Yazdanparast indicated that the over-activation of signal 
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transducer and activator of transcription protein 3 (STAT3) has been associated with trastu-
zumab resistance. This suggests that STAT3 acts as a prognostic indicator of trastuzumab resis-
tance in primary HER2-positive breast cancer [39]. More than 50% of breast cancer patients 
with aggressive and chemotherapeutic resistant condition have been detected with the phos-
phorylation of STAT3. Abnormal STAT3 activation due to alterations in HER2, HER1, BRCA1, 
and ER leads to deregulation of cell proliferation, migration, survival and angiogenesis. Several 
up-regulated genes including hypoxia inducible factor 1 alpha (HIF-1α) as a result of unex-
pected STAT3 activation have been implicated in trastuzumab resistance. During their study, 
Aghazadeh and Yazdanparast found that HIF-1α is an essential signaling element required to 
downregulate phosphatase and tensin homolog (PTEN) via Hes Family BHLH Transcription 
Factor 1 (HES-1) repressor during the induction of trastuzumab resistance [39]. Similarly, 
Sonnenblick et al. provide convincing evidence for a link between phosphorylation of STAT3 
and trastuzumab resistance in HER2 positive primary breast cancers. Patients with activated 
STAT3 may suggest novel approaches to block the STAT3 pathway in combination with trastu-
zumab treatment particularly in PTEN-deleted breast cancer [40]. Additionally, it has been 
observed that inhibition of IL6-STAT3 pathway in PTEN-deleted HER2 positive breast cancer 
leads to decrease in the population of cancer stem cells and inhibits the development of dis-
tance metastasis using IL6R antibody alone or in combination with trastuzumab [41].
5. Other receptors involved in breast cancer
5.1. NOTCH signaling pathway
Notch signaling pathway within the breast cancer field attracted a huge number of research 
scientists over the past decade. It has been observed that Notch signaling is aberrantly acti-
vated in breast cancer and affects a number of cellular processes such as apoptosis, prolif-
eration and cancer stem cell activity. The Notch signaling pathway consists of four receptors 
(Notch1, Notch2, Notch3 and Notch4) and five Delta/Serrate/LAG-2 (DSL) ligands Jagged1, 
Figure 3. TKIs and MAbs target HERs for the treatment of breast, lung and several other types of cancer. Modified from 
Alanazi and Khan [16].
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Jagged2, Delta-like1 (Dll1, Dll3 and Dll4). The activation of Notch signaling pathway occurs 
by the interaction of DSL ligands with Notch receptors on adjacent cells. This interaction 
induces a proteolytic cleavage of the Notch protein at the S2 cleavage site mediated by two 
enzymes, Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and 
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17). After this 
cleavage, the remaining part of the Notch protein will be cleaved by the γ-secretase enzyme 
complex and releases the Notch intracellular domain (NICD). Finally, NICD translocates 
to the nucleus and forms a complex with DNA-binding protein recombination signal bind-
ing protein for immunoglobulin Kappa J region (RBPj) and a member of the mastermind-
like (MAML) family transcriptional coactivators (Figure 4). This complex activates various 
target genes of Notch pathway that are associated with tumorigenesis [42], cell growth, 
differentiation, and cell survival [43].
A number of studies indicate that aberrant activation of Notch signaling has been observed in 
breast cancer. The high expression of Notch signaling pathway components including Dll1, 
Dll3 and Dll4, Jagged1–2 and Notch receptors has been observed in invasive breast cancer. 
This expression is associated with poor prognosis in breast cancer patients [43, 44]. Due to 
the important role of Notch signaling pathway in breast cancer, it becomes a very attrac-
tive therapeutic target. At present, several classes of Notch inhibitors have been developed 
and are under various clinical trials including γ-secretase inhibitor (GSI), monoclonal anti-
bodies against Notch receptors or ligands and small interfering RNA (siRNA).GSI effectively 
represses cancer stem cells (CSCs) in in vitro studies and triggers apoptosis via inhibiting 
proteasome activity and enhancing endoplasmic reticulum (ER) stress in tumor cells [45].
Several GSIs have completed pre-clinical and early clinical trials including RO4929097 
which significantly sensitizes putative breast cancer stem cells to ionizing radiation and 
may be effective in treating inflammatory breast cancer (IBC), MRK-003 in combination with 
trastuzumab induced tumor regression and prevented tumor recurrence post-trastuzumab 
Figure 4. Basics of notch signaling pathway. Modified from Acar et al. [42].
Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis
http://dx.doi.org/10.5772/intechopen.74679
115
treatment in HER2 positive breast xenografts and partially reverses trastuzumab resistance 
in vivo, MK-0752 reduced breast cancer stem cell subpopulation in vitro and in human tissues 
and PF-03084014 exhibited antitumor and antimetastatic activity in breast xenograft models 
(Table 3) [45].
5.2. The Wnt/β-catenin pathway
The Wnt/β-catenin pathway plays an important role in both normal development and 
tumorigenesis. The initiation of Wnt/β-catenin pathway occurs via conserved growth fac-
tors of the wingless and integration site growth factor (Wnt) family. Nineteen different Wnt 
genes which share a high level of sequence homology encode Wnts. Binding of Wnts to cell 
surface receptors lead to the activation of Wnt pathway by triggering signaling cascades that 
are very crucial in many cellular functions including survival, cell proliferation, specification 
of cell fate, migration and polarity and self-renewal property of stem cells [46]. Canonical 
Wnt pathway is also known as β-catenin-dependent Wnt pathway. In the absence of this 
signaling, β-catenin is maintained at a low level via ubiquitin/proteasome-mediated degrada-
tion. This can be regulated through protein destruction complex consisting of adenomatous 
polyposis coli (APC), axin and glycogen synthase kinase-3β (GSK-3β). Binding of Wnt ligand 
to a seven-pass transmembrane Frizzled (FZD) receptor in combination with its co-receptor, 
low-density lipoprotein receptor-related protein 6 (LRP6) or its close relative LRP5leads to 
the activation of Wnt signaling pathway.. The formation of Wnt/FZD/LRP6 complex with the 
recruitment of the scaffolding protein Disheveled (Dvl) leads to LRP6 phosphorylation and 
recruitment of the Axin complex to the receptors. As a result, Axin-mediated β-catenin phos-
phorylation gets inhibited and β-catenin will be stabilized in the cytoplasm. Accumulated 
β-catenin translocates to the nucleus to form complexes with T cell factor/lymphoid enhancer 
factor (TCF/LEF) family of proteins and activates target gene expression of Wnt signaling 
pathway (Figure 5) [47].
It has been noticed that aberrant activation of canonical Wnt pathway, which supports the 
formation and the maintenance of cancer stem cells (CSCs), maintains the pluripotency of 
the stem cells instead of allowing them to differentiate leading to neoplastic proliferation. 
Dysregulation in any components of this pathway accelerates tumor growth [46].
Triple-negative breast cancers (TNBC) is considered to be the most difficult subtype to treat 
due to the lack of effective targeted therapy. It has been observed that Wnt/β-catenin sig-
naling is activated in TNBC patients with the upregulation of its components. The over-
activation of this signaling with the upregulation of Wnt receptor expression in TNBC and 
basal-like breast cancer (BLBC) advocates this signaling pathway might be utilized as thera-
peutic target for TNBC/BLBC. For instance, salinomycin has been identified as an inhibitor 
of LRP6 expression and Wnt/β-catenin signaling and also as a selective killer of breast cancer 
stem cells. Another example is mesoderm development (Mesd), which has been identified as 
a specialized chaperone for LRP5/6 and acts as an LRP6 antagonist. Several other Wnt path-
way inhibitors are in clinical trials such as OMP-18R5, OMP-54F28 and OTSA101 targeting 
FZD7, FZD8 and FZD10, respectively, as summarized in Table 3. Drugs targeting β-catenin 
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are also being tested [48]. Thus, effective treatment of TNBC by targeting Wnt signaling 
pathway is highly anticipated and would prove immensely beneficial in conquering this 
deadly disease.
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GSK-3β axin and glycogen synthase kinase-3β
Figure 5. Schematic representation of canonical Wnt signaling pathway. Modified from Kazi et al. [46].
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BLBC basal-kike breast cancer
CSCs cancer stem cells
DSL Delta/Serrate/LAG-2
Dll1 delta-like1
Dvl Disheveled
DCIS ductal carcinoma in situ
ER endoplasmic reticulum
HER2 epidermal growth factor receptor 2
ER estrogen receptor
FZD frizzled
IHC immunohistochemistry
IBC inflammatory breast cancer
LRP6 lipoprotein receptor-related protein 6
MAML member of the mastermind-like
ADAM10 metalloproteinase domain-containing protein 10
MAPK mitogen-activated protein kinase
MAbs monoclonal antibodies
NICD notch intracellular domain
PI3K phosphoinositide 3-kinase
PR progesterone receptor
PKB Or AKT protein kinase B
RBPj recombination signal binding protein for immunoglobulin kappa J region
STATS signal transducer and activator of transcription
siRNA small interfering RNA
TKIs tyrosine kinase inhibitors
TCF/LEF T cell factor/lymphoid enhancer factor
RTKs transmembrane receptor tyrosine kinases family
TNBC triple-negative breast cancer
GSI γ-secretase inhibitor
Breast Cancer and Surgery118
Author details
Ibrahim O. Alanazi1* and Zahid Khan2
*Address all correspondence to: ialenazi@kacst.edu.sa
1 National Center for Biotechnology, King Abdulaziz City for Science and Technology 
(KACST), Saudi Arabia
2 Genome Research Chair, Department of Biochemistry, College of Science, King Saud 
University, Riyadh, Kingdom of Saudi Arabia
References
[1] Jemal A et al. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61(2):69-90
[2] Jemal A et al. Global patterns of cancer incidence and mortality rates and trends. Cancer 
Epidemiology, Biomarkers & Prevention. 2010;19(8):1893-1907
[3] Sarkar S, Mandal M. Breast cancer: Classification based on molecular etiology influenc-
ing prognosis and prediction. Gunduz PM. editor, In: Breast Cancer - Focusing Tumor 
Microenvironment, Stem cells and Metastasis, 2011. https://www.intechopen.com/
books/breast-cancer-focusing-tumor-microenvironment-stem-cells-and-metastasis/
breast-cancer-classification-based-on-molecular-etiology-influencing-prognosis-and-
prediction
[4] Kaminska M et al. Breast cancer risk factors. Prz Menopauzalny. 2015;14(3):196-202
[5] Anders CK et al. Breast cancer before age 40 years. Seminars in Oncology. 2009;36(3): 
237-249
[6] Singletary SE. Rating the risk factors for breast cancer. Annals of Surgery. 2003;237(4): 
474-482
[7] Malhotra GK et al. Histological, molecular and functional subtypes of breast cancers. 
Cancer Biology & Therapy. 2010;10(10):955-960
[8] Recommendations for the reporting of breast carcinoma. Association of Directors of 
Anatomic and Surgical Pathology. American Journal of Clinical Pathology. 1995;104(6): 
614-619
[9] Lester SC et al. Protocol for the examination of specimens from patients with invasive 
carcinoma of the breast. Archives of Pathology & Laboratory Medicine. 2009;133(10): 
1515-1538
[10] Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive duc-
tal carcinoma of the breast: Results and therapeutic implications. Therapeutic Advances 
in Medical Oncology. 2016;8(4):261-266
Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis
http://dx.doi.org/10.5772/intechopen.74679
119
[11] Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Archives of Gynecology 
and Obstetrics. 2016;293(2):247-269
[12] Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of 
intrinsic tumor subtypes. Biochimica et Biophysica Acta. 2015;1856(1):73-85
[13] Hon JDC et al. Breast cancer molecular subtypes: From TNBC to QNBC. American 
Journal of Cancer Research. 2016;6(9):1864-1872
[14] Nielsen TO et al. Immunohistochemical and clinical characterization of the basal-like 
subtype of invasive breast carcinoma. Clinical Cancer Research. 2004;10(16):5367-5374
[15] Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. The New England 
Journal of Medicine. 2009;360(8):790-800
[16] Alanazi IO, Khan Z. Understanding EGFR signaling in breast cancer and breast cancer 
stem cells: Overexpression and therapeutic implications. Asian Pacific Journal of Cancer 
Prevention. 2016;17(2):445-453
[17] Rakha EA et al. Morphological and immunophenotypic analysis of breast carcinomas with 
basal and myoepithelial differentiation. The Journal of Pathology. 2006;208(4):495-506
[18] van de Rijn M et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcino-
mas with poor clinical outcome. The American Journal of Pathology. 2002;161(6):1991-1996
[19] Krishnamurthy S et al. Triple negative breast cancer - our experience and review. Indian 
Journal of Surgical Oncology. 2012;3(1):12-16
[20] Osborne CK et al. Crosstalk between estrogen receptor and growth factor receptor 
pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer 
Research. 2005;11(2 Pt 2):865s-870s
[21] Allred DC. Issues and updates: Evaluating estrogen receptor-alpha, progesterone recep-
tor, and HER2 in breast cancer. Modern Pathology. 2010;23(Suppl 2):S52-S59
[22] Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: An 
overview of the proposed roles of noncoding RNA. Breast Cancer Research : BCR. 
2015;17:40
[23] Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen 
receptor signaling. The Journal of Biological Chemistry. 2001;276(40):36869-36872
[24] Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Molecular 
Endocrinology (Baltimore, Md.). 2005;19(8): pp. 1951-1959
[25] Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches 
in breast cancer. Breast Cancer Research. 2015;17:60
[26] Simpson ER et al. Aromatase cytochrome P450, the enzyme responsible for estrogen 
biosynthesis. Endocrine Reviews. 1994;15(3):342-355
Breast Cancer and Surgery120
[27] Simpson ER. Sources of estrogen and their importance. The Journal of Steroid Biochemistry 
and Molecular Biology. 2003;86(3-5):225-230
[28] Shou J et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu 
cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute. 
2004;96(12):926-935
[29] Schettini F et al. Hormone receptor/human epidermal growth factor receptor 2-positive 
breast cancer: Where we are now and where we are going. Cancer Treatment Reviews. 
2016;46:20-26
[30] Gilani RA et al. The importance of HER2 signaling in the tumor-initiating cell population 
in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment. 
2012;135(3):681-692
[31] Bosco EE, Knudsen ES. RB in breast cancer: At the crossroads of tumorigenesis and treat-
ment. Cell Cycle. 2007;6(6):667-671
[32] Lehn S et al. A non-functional retinoblastoma tumor suppressor (RB) pathway in 
premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle. 
2011;10(6):956-962
[33] Choi HJ et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in Tamoxifen resis-
tance in breast cancer. Journal of the National Cancer Institute. 2018;110(4). DOI: 10.1093/
jnci/djx207
[34] Anderson WF et al. Estrogen receptor breast cancer phenotypes in the surveillance, epi-
demiology, and end results database. Breast Cancer Research and Treatment. 2002;76(1): 
27-36
[35] Sari E, Yalcin S. Clinical aspects of estrogen and progesterone receptors and ERBB2 test-
ing. Aydiner A, İğci A, Soran A, Editors. In: Breast Disease: Diagnosis and Pathology. 
Cham: Springer International Publishing; 2016. p. 161-185
[36] Spector NL, Blackwell KL. Understanding the mechanisms behind Trastuzumab ther-
apy for human epidermal growth factor receptor 2–positive breast cancer. Journal of 
Clinical Oncology. 2009;27(34):5838-5847
[37] Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: 
Overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748
[38] Segovia-Mendoza M et al. Efficacy and mechanism of action of the tyrosine kinase 
inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast 
cancer: Preclinical and clinical evidence. American Journal of Cancer Research. 2015; 
5(9):2531-2561
[39] Aghazadeh S, Yazdanparast R. Activation of STAT3/HIF-1alpha/Hes-1 axis promotes 
trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation 
of PTEN. Biochimica et Biophysica Acta. 2017;1861(8):1970-1980
Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis
http://dx.doi.org/10.5772/intechopen.74679
121
[40] Sonnenblick A et al. Constitutive phosphorylated STAT3-associated gene signature is 
predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC 
Medicine. 2015;13:177
[41] Korkaya H et al. Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance 
in HER2+ breast cancer by expanding the cancer stem cell population. Molecular Cell. 
2012;47(4):570-584
[42] Acar A et al. A role for notch signalling in breast cancer and endocrine resistance. Stem 
Cells International. 2016;2016:2498764
[43] Reedijk M et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast 
cancer and is associated with poor overall survival. Cancer Research. 2005;65(18):8530-8537
[44] Mittal S et al. Cooperation of notch and Ras/MAPK signaling pathways in human breast 
carcinogenesis. Molecular Cancer. 2009;8(1):128
[45] Yuan X et al. Notch signaling: An emerging therapeutic target for cancer treatment. 
Cancer Letters. 2015;369(1):20-27
[46] Kazi M et al. The potential of Wnt signaling pathway in cancer: A focus on breast cancer. 
Cancer Translational Medicine. 2016;2(2):55-60
[47] MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: Components, mechanisms, and 
diseases. Developmental Cell. 2009;17(1):9-26
[48] King TD, Suto MJ, Li Y. The wnt/β-catenin signaling pathway: A potential therapeutic 
target in the treatment of triple negative breast cancer. Journal of Cellular Biochemistry. 
2012;113(1):13-18
Breast Cancer and Surgery122
